IRAK4 and acute myeloid leukemia: CA-4948 is a potent interleukin-1 receptor-associated kinase 4 (IRAK-4)/FLT3 inhibitor, with potential for anti-tumor activity in AML, that is currently in the early phases of therapeutic development (NCT04278768).